- RecruitingPHASE3
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
This study looks at a new medicine called benralizumab for children aged 6 to 18 with severe asthma. It wants to see if the medicine can stop asthma attacks and if it's safe. Half the children get the medicine, and half get a dummy medicine.
For: AsthmaUnited States · Argentina · Canada - RecruitingPHASE3
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study looks at a new treatment called benralizumab for people with severe asthma. It compares adding benralizumab to your usual asthma inhaler with just increasing the dose of your inhaler. We want to see if benralizumab helps control asthma better and is safe.
For: Eosinophilic AsthmaUnited States · Bulgaria · Canada - Active not recruitingPHASE4
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
This study looks at how a medicine called benralizumab affects the lungs of people with severe asthma. It aims to see if the treatment can improve lung structure and how well the lungs work in people whose asthma isn't controlled by usual medicines.
For: AsthmaUnited States · Canada · Denmark - Active not recruitingPHASE3
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
This study looks at a new drug called benralizumab for Hypereosinophilic Syndrome (HES) in people aged 12 and over. It compares benralizumab to a dummy drug to see if it's safe and helps reduce HES symptoms.
For: Hypereosinophilic SyndromeUnited States · Argentina · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)
This study is testing a new medicine, benralizumab, for people with moderate to very severe COPD who have frequent flare-ups and high levels of a certain type of white blood cell called eosinophils. It aims to see if the medicine can reduce these flare-ups and if it's safe.
For: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood EosinophilsNetherlands · Spain · Sweden - Active not recruitingPHASE3
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
This study compares two treatments, benralizumab and mepolizumab, for a rare condition called Eosinophilic Granulomatosis with Polyangiitis (EGPA). Researchers want to see which one works better and is safer for people whose EGPA keeps coming back or isn't well controlled, even with other medicines.
For: Eosinophilic Granulomatous VasculitisUnited States · Belgium · Canada